TransCure bioServices raises € 0.7 million

TCS is a leading contract research organization providing services to pharmaceutical, biotech, start-up and academic researchers who need faster, smarter and cost-effective solutions for drug profiling and development. Uniquely designed animal models with functional humanized systems have been developed to provide predictive in vivo pharmacology testing and preclinical lead candidate selection / validation.

TransCure bioServices is located in both Switzerland and France and is a spin-off from TransCure Biosciences (Geneva), the Universities of Geneva, Pretoria, and Zürich.

“This investment will allow us to highlight the uniqueness and usefulness of our fully functional humanized platforms for inflammatory and infectious diseases, immunotoxicity testing and vaccine development” explains Dr. Patrick Nef, co-founder and President of TCS.

“The functional reconstitution of the human immune system in animal models is the basis of our expertise and we provide customer-oriented services by designing tailored-made protocols, diligently and carefully performing experiments, offering wide range of data analysis, plus comprehensive report drafting. We are a “one-stop-shop” for predictive in vivo pharmacology studies.”

TCS was established to develop humanized mouse platforms in its own state-of-the-art and accredited biosafety level 2 and 3 (BSL2 and BSL3) animal facilities and laboratories, allowing to test infectious and non-infectious diseases such as HIV, HCV, HBV, Tuberculosis, inflammation and auto-immune diseases, rheumatoid arthritis, inflammatory bowel disease , multiple sclerosis, Lupus or parasitic diseases.